A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Advanced breast cancer; Meningeal carcinomatosis
- Focus Therapeutic Use
- 09 Apr 2019 Status changed from not yet recruiting to recruiting.
- 03 Jan 2019 Planned initiation date changed from 1 Oct 2018 to 15 Mar 2019.
- 06 Sep 2018 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.